Search results for "Diabetes"
Earn trust, counter misinformation
Physicians are on the front lines of addressing medical misinformation, increasingly figuring out what to address and how.
https://immattersacp.org/archives/2023/06/earn-trust-counter-misinformation.htm
1 Jun 2023
Statins' benefits outweigh their association with diabetes incidence
Statins' benefits outweigh the risk of diabetes for patients taking the drugs for secondary prevention and those at high risk of major adverse coronary events, a study found.
https://immattersacp.org/weekly/archives/2012/08/14/4.htm
14 Aug 2012
Thrombolysis may benefit acute ischemic stroke patients with diabetes and prior stroke
Thrombolysis appeared to benefit patients with acute ischemic stroke who had concomitant diabetes or a history of stroke, according to a new study.
https://immattersacp.org/weekly/archives/2011/11/22/6.htm
22 Nov 2011
Silent epidemic: Alcohol and preventable death, despair
Alcohol use disorder is often linked to poverty, unemployment, social isolation, and other social determinants of health, and medicine must address these underlying factors to genuinely reduce the risks associated with alcohol.
https://immattersacp.org/archives/2023/07/silent-epidemic-alcohol-and-preventable-death-despair.htm
1 Jul 2023
More compounded products recalled, diabetes drug approved
This regulatory update covers a recall of a compounding pharmacy's products due to mold and approval of a sodium-glucose co-transporter for diabetes.
https://immattersacp.org/archives/2013/06/fda.htm
1 Jun 2013
Be on alert for blood cancer precursors
Joseph R. Mikhael, MD, FACP, reviewed practical approaches to two premalignant conditions, monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL).
https://immattersacp.org/archives/2023/07/be-on-alert-for-blood-cancer-precursors.htm
1 Jul 2023
Choice of third oral diabetes drug can depend on each patient's needs
There is no clear choice for a third oral agent for controlling A1c levels above 7% following metformin and a sulfonylurea, researchers concluded from a meta-analysis of type 2 diabetics, so the best choice depends on the patient's need.
https://immattersacp.org/weekly/archives/2011/05/17/1.htm
17 May 2011
Updated warnings on fluoroquinolones, new diabetes drug
This column reviews a warning on fluoroquinolones with a risk of disabling and potentially permanent side effects, as well as approval of an injection to improve glycemic control in adults with type 2 diabetes.
https://immattersacp.org/archives/2016/10/fda.htm
1 Oct 2016
Treatment pathways compared for diabetic peripheral neuropathy
Amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective for controlling pain, a recent study found.
https://immattersacp.org/weekly/archives/2022/08/30/2.htm
30 Aug 2022
GLP-1 receptor agonists may offer kidney protection in patients with type 2 diabetes
An industry-conducted pooled analysis of two large trials of glucagon-like peptide-1 (GLP-1) receptor agonists found that both semaglutide and liraglutide slowed kidney function decline, with semaglutide appearing to have the greatest effect.
https://immattersacp.org/weekly/archives/2021/12/21/2.htm
21 Dec 2021